Arrowhead Pharmaceuticals, Inc. (ARWR) Earnings History
Annual and quarterly earnings data from 1997 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 97.1% | 11.9% | -0.2% |
| 2024 | 100.0% | -16927.1% | -16882.4% |
| 2023 | 100.0% | -85.2% | -85.3% |
| 2022 | 100.0% | -73.4% | -72.4% |
| 2021 | 100.0% | -107.8% | -101.9% |
Download Data
Export ARWR earnings history in CSV or JSON format
Free sign-in required to download data
Arrowhead Pharmaceuticals, Inc. (ARWR) Earnings Overview
As of March 2, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) reported trailing twelve-month net income of $202M, reflecting +1.0% year-over-year growth. The company earned $1.44 per diluted share over the past four quarters, with a net profit margin of -0.0%.
Looking at the long-term picture, ARWR's historical earnings data spans multiple years. The company achieved its highest annual net income of $68M in fiscal 2019.
Arrowhead Pharmaceuticals, Inc. maintains positive profitability with a gross margin of 1.0%, operating margin of 0.1%, and net margin of -0.0%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including ALNY ($314M net income, 0.1% margin), IONS (-$381M net income, -0.4% margin), CRSP (-$488M net income, -165.7% margin), ARWR has room to improve margins relative to the peer group. Compare ARWR vs ALNY →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
29 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$2M | +99.7% | $98M | $-0.01 | -0.2% | 11.9% |
| 2024 | -$599M | -192.0% | -$601M | $-5.00 | -16882.4% | -16927.1% |
| 2023 | -$205M | -16.6% | -$205M | $-1.92 | -85.3% | -85.2% |
| 2022 | -$176M | -25.0% | -$179M | $-1.67 | -72.4% | -73.4% |
| 2021 | -$141M | -66.6% | -$149M | $-1.36 | -101.9% | -107.8% |
| 2020 | -$85M | -224.4% | -$93M | $-0.84 | -96.1% | -105.9% |
| 2019 | $68M | +224.8% | $61M | $0.69 | 40.3% | 36.3% |
| 2018 | -$54M | -58.4% | -$56M | $-0.65 | -337.3% | -346.5% |
| 2017 | -$34M | +57.9% | -$37M | $-0.47 | -109.5% | -117.8% |
| 2016 | -$82M | +11.1% | -$82M | $-1.34 | -51614.6% | -51627.1% |
See ARWR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARWR Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ARWR vs AGIO
See how ARWR stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ARWR growing earnings?
ARWR EPS of $1.44 reflects slowing growth at +1.0%, below the 5-year CAGR of N/A. TTM net income is $202M. Expansion rate has moderated.
What are ARWR's profit margins?
Arrowhead Pharmaceuticals, Inc. net margin is -0.0%, with operating margin at +0.1%. Below-average margins reflect competitive or cost pressures.
How consistent are ARWR's earnings?
ARWR earnings data spans 1997-2025. The current earnings trend is +1.0% YoY. Historical data enables comparison across business cycles.